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This study focused on the association of extrinsic alkaline phosphatase (AP) activity with both 
early and advanced calcification of glutaraldehyde-pretreated bovine pericardial bioprosthetic 
(GPBP) tissue, and the inhibition of both calcification and AP activity by pre-incubation in 
diphosphonates (sodium-ethanehydroxydiphosphonate [NaEHDP], 
aminopropanehydroxydiphosphonate IAPD]) and metallic salts (FeCI,, Ga(NO&, AIQ). GPBP 
specimens were implanted subcutaneously in 3 wk old male rats after ore-incubation. Following 
explantation of the tissue at 72 h and 21 d, calcification was assessed tnorphologically by light 
microscopy and chemically by atomic adsorption spectroscopy for calcium content and by 
molybdate complexation for phosphorus. AP activity was characterized by enzymatic hydrolysis 
of paranitrophenyl phosphate and by histochemical studies. In both control and pretreated 
groups, AP levels were greater in 72 h explants than 21 d retrievals, which demonstrated 
extensive calcification in control explants. All pre-incubations that resulted in inhibition of 
calcification after 21 d, except for APD, were associated with 72 h AP content which was lower 
than control specimens. The typical time of initiation of calcification was 72 h, as determined by 
previous studies with this model system. Covalently bound APD inhibited calcification. Increased 
AP activity in the APD group may be due to the toxicity of this agent with resultant acute 
inflammation, or other incompletely understood effects of diphosphonates on calcification and 
AP. Furthermore, EHDP and Ga3’ incubations were also associated with decreased GPBP AP at 
72 h compared to control, but were not effective for inhibiting calcification after 21 d. We 
concluded that inhibition of peak GPBP AP activity is not necessarily associated with the 
prevention of GPBP mineralization. 
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Bioprosthetic heart valves fabricated from either glutar- 
aldehyde-pretreated porcine aortic valve cusps or bovine 
pericardium [GPBP) are often used to replace deteriorating 
human cardiac valves. The primary reason for the 
clinical failure of porcine aortic valve bioprostheses is 
dystrophic calcification1-3. Calcification also contributes 
to the failure of bovine pericardial valves. Bioprosthetic 
heart valve calcification occurs as a multifactorial 
process, in which an interaction of host factors (youth), 
implant factors (glutaraldehyde fixation] and implant 
factors (stress-strain) are crucial’-“. Calcification of 
clinical bioprosthetic valves can be simulated either by 
Correspondence to Dr D. Hirsch. 
large animal circulatory models or by subdermal implants 
in rodents*-“. The initial calcification event in the rat 
subdermal model is the mineral deposition in devitalized 
cells intrinsic to the bioprosthetic tissue within 48-72 h, 
followed later by collagen mineralization. 
Matrix vesicles (MV) present in the extracellular 
matrix of mineralizing tissues are considered to initiate 
deposition of hydroxyapatite mineral in endochondral 
bone formation and calcific diseases’. An enrichment of 
alkaline phosphatase (AP) within the MVs suggests an 
important role for this enzyme in the initiation of 
calcificationa’ ‘; following nucleation, AP activity declines 
during progressive bone mineralization”. However, 
some studies have shown that AP catalytic activity is not 
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absolutely required for MV calcification”. The fact that 
the enzyme was found distributed widely in tissues that 
normally do not undergo mineralization has raised 
questions as to the specificity of the relationship between 
AP and calcification”. 
Research has demonstrated AP activity in glutar- 
aldehyde-pretreated porcine aortic valve tissue” and 
GPBP13 before and after glutaraldehyde fixation, 
However, after fixation AP activity is only detectable by 
histochemistry, and is not extractable using the established 
butanol extraction procedure13. Fu~hermore, subdermal 
implant studies have demonstrated peak extractable AP 
levels in GPBP after 72 h implantation, coinciding with 
the onset of calcification’3. AP activity declined there- 
after, while bulk mineral increased13. In previous studies, 
metallic salt pre-incubations, which included either 
ferric chloride or aluminium chloride, have been shown 
to inhibit calcification of GPBP tissues in the rat 
subdermal model’4* *‘. This inhibition was associated 
with reduced AP activity after 21 d13. These metallic 
inhibitors have also been shown to be localized to the site 
at which AP is present15. This is probably due to the high 
affinity of these cations for membrane-associated 
phosphorus-rich sites, which have also been shown to be 
the loci of the initial calcific deposits. Furthermore, 
diphosphonates are potent calcification inhibitors’6-‘8. 
Their mechanism of action appears to be the marked 
affinity of these compounds for crystalline calcium 
phosphateslg. “. In addition, diphosphonates also influence 
cellular metabolism; dichloromethanediphosphonate 
and sodium ethanehydroxydiphosphonate increased the 
AP activity of cultured rat calvaria cell?, and in viva, 
chickens treated with these diphosphonates demonstrated 
inhibition of bone mine~lization associated with increased 
AP activity”. 
The present study was carried out to understand the 
effects of diphosphonates and metallic salts on both 
calcification and AP activity during dystrophic mineral- 
ization of rat subdermal implants of GPBP. The goals of 
this study were to: (1) document the effects of various 
inhibitors of GPBP calcification on early (72 h) and late 
(21 d) mineralization and AP accumulation in rat 
subdermal implants; (2) to examine further the morpho- 
logic distribution of AP with either progression or 
inhibition of GPBP mineralization: and (3) to assess the 
effects of possible calcification inhibitors on the Ca-P 
mineral phase, as indicated by Ca/P ratios, 
MATERIALS AND METHODS 
Materials 
Electron microscopy-grade glutaraldehyde was purchased 
as an 8% aqueous solution (Polyscience, Warrington, PA, 
USA). The buffer used for cross-linking and incubation 
of the drugs included 50 mM N-2-hydroxyethylpiperazine- 
~‘-2-ethanesulphonic acid (HEPES, Sigma Chemical, St 
Louis, MO, USA) with 0.1 M NaCl (EM Science, Cherry 
Hill, NJ, USA). Ferric chloride hexahydrate (reagent 
grade) and the phosphate standard were obtained from 
Sigma Chemical, St Louis, MO, USA. Gallium nitrate 
(99%) and ammonium molybdate (VI) were obtained from 
Aldrich (Milwaukee, WI, USA). Aluminium chloride 
was obtained from Mallinckrodt (Paris, KY, USA), 
Aminopropanehydroxydiphosphonate (APD) was donated 
by Dr James Benedict (Intermedics O~hopedics Inc., 
Wheatridge, CO, USA). Sodium ethanehydroxydiphos- 
phonate (NaEHDP) was donated by Procter and Gamble 
(Cincinnati, OH, USA). L-ascorbic acid was purchased 
from Fisher Chemical (FairLawn, NJ, USA), 2-amino-2- 
methyl-l-propanol, set-butanol, p-nitrophenyl phosphate 
(pnpp) and p-nitrophenol (pnp) were also obtained from 
Sigma. 
Methods 
In vitro incubations 
Fresh mature bovine parietal perica~ium was obtained 
from the slaughter house (P. Dunbar, Milan, MI, USA) 
and immediately cross-linked for 24 h in 0.6% glutar- 
aldehyde at pH 7.4 (50 mM HEPES buffer) at 4”C, then 
stored for 2-4 wk in 0.2% glutaraldehyde in the same 
buffer at 4”C, as described previously5,6123. GPBP was 
cut into 1 cm diameter pieces and rinsed free of 
glutaraldehyde. 
Following fixation and storage, the GPBP pieces were 
pre-incubated for 24 h at room temperature in either 
APD, or NaEHDP both at concentrations of 0.1 M, 
buffered to pH 7.4 plus NaCl(O.1 M). GPBP pieces were 
also pre-incubated in several metallic salt solutions at 
pH 3 (0.001 M HCl, NaCl 0.1 M) including AlCl, (0.1 M), 
Ga(NO,), (0.1 M), FeCl, (both 0.1 M and lo-* M). Control 
specimens of GPBP were pre-incubated in either pH 7.4 
(50 mM HEPES) or pH 3(0.001 M HCl) solutions (0.1 M 
NaCl) for 24 h at room temperature. 
Im~iant and ~trjeva~ methods 
After pie-incubation in the various solutions, the GPBP 
specimens were washed with sterile saline, and then 
implanted subdermally in male, weanling rats (50-60 g, 
CD, Sprague-Dawley, Charles River Laboratories, 
Burlington, MA, USA) according to methods described 
previously ‘, ‘3 15* “9 23, The rats were anaesthetized by an 
i.m. injection of ketamine hydrochloride and xylazine. 
Ten GPBP specimens were implanted subdermally per 
rat (six in the abdominal wall and four in the dorsal wall) 
(five rats per group study). At 72 h, five pieces (from the 
abdominal implant site) were removed under anaesthesia. 
After 21 d, the rats were killed by CO, asphyxiation and 
the remaining samples retrieved. 
Biochemical analysis 
Explants were rinsed with copious volumes of saline and 
deionized water, freeze-dried, minced and subjected to 
acid hydrolysis as described previously5, 23, Aliquots of 
the hydrolysates were analysed for calcium by atomic 
absorption and for phosphorus using a molybdate 
complexationz4. AP enzymatic activity was quantitated 
as described previously . l2 Briefly, butanol extracts of 5- 
6 mg GPBP samples were assayed for hydrolysis of pnpp 
normalized by Lowry protein contentz5 (pH 10.4 and 
37% at a wave length of 405 nm using a Lambda 3B 
spectrophotometer (Perkin-Elmer, Oak Brook, IL, USA). 
A representative sample of each GPBP explant was 
placed in Karnovsky’s fixative’” for subsequent morpho- 
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Table 1 Inhibition of glutaraldehyde pretreated bovine pericardium (GPBP) calcification and alkaline phosphatase(AP) activity: rat 
subdermal implant results 
Pretreatment 72 h Explants 21 d Explants 
Ca’ P’ AP” Ca/P”’ Ca’ P’ AP” Cal P”’ 
Control (pH 7.4) 2.2 + 0.20(4) 0.7 f 0.10(4) 317.30 f 41.4(7) 2.7 90.0 + 5.9(4) 45.20 f 2.3(4) 78.2 + 15.2(4) 1.5 
APD (0.1 M) 2.1 f 0.60(5) 1.4 f 0.60(5) 576.60 + 85.0(12)+ 1.1 3.4 + 0.6(5)t 1.50 f 0.2(5) 101.7 f 20.0(9) 1.7 
NaEHDP (0.1 M) 1.5 f 0.06(S) 0.4 f 0.04(5) 165.60 f 14.3(13)+ 3.3 89.3 + 8.7(5) 84.20 f 24.2(5) 52.4 + 6.9(10) 0.8 
Control (pH 3) 3.2 i 1.40(2) 0.6 f 0.30(2) 249.60 + 49.2(g) 4.3 95.6 + 25.9(3) 52.00 f 13.6(3) 42.9 f 5.8(6) 1.4 
FeCI, (0.1 M) 4.8 C 2.9 + 
FeCI,(10-4M) 
0.30(5) O.lO(5) 185.90 + 34.1(13) 1.2 19.0 ?I 3.0(5)t 12.30 f 2.2(5) 157.6 f 76.6(10) 1.2 
2.3 rt 0.50(5) 1.04 C 0.20(5) 490.10 f 145.3(14) 1.7 93.3 + 14.2(5) 50.60 f 8.1(5) 87.4 f 7.7(lO)t 1.4 
Ga(NO,), (0.1 M) 5.2 f 0.80(S) 2.3 + 0.30(5) 217.00 f 34.6(12) 1.7 98.0 + 5.34(5) 102.30 f 29.2(5) 103.6 f 40.0(10) 0.7 
AU, (0.1 M) 9.8 f 0.60(5) 7.4 i- 0.40(5) 93.07 f 8.5(12)t 1.7 9.3 + OS(5)t 25.26 ? 4.3(5) 33.7 + 2.6(10) 0.3 
Mean t SEM. 
* pg/mg of dried tissue. 
** nm paranitrophenyl phosphatelminlmg protein. 
‘** Molar ratio. 
t P < 0.05 compared with controls. 
( ) Number in parentheses is the number of analyses. 
logical analysis. For histochemical demonstration of AP, 
a separate GPBP explant sample from each drug group 
were frozen with dry ice in several drops of OCT medium 
(Miles Inc., Elkhart, IN, USA] for subsequent cryo- 
microtomy and AP staining assessment, using the 
conventional methodz7. Sections of GPBP (10 pm thick] 
were cut with a cryomicrotome, mounted on glass slides, 
and dried at room temperature. The sections were 
incubated at 37°C for 30 min in a medium for AP 
modified from Gomoriz7 containing 50 ml of 5 mM MgCl, 
in distilled water, 1 ml Naphtol AS-MX phosphate in 
pH 10.5 buffer (Sigma), and 25 mg Fast Red TR or Fast 
Blue RR (Sigma) as described previously”. 
RESULTS 
The calcium and phosphorus levels, together with the AP 
activity data at 72 h and 21 d, are summarized in Table 1. 
No extractable AP activity from unimplanted GPBP was 
noted by enzymatic analyses. Explant GPBP AP enzymatic 
activity was higher in all groups after 72 h than in 21 d 
explants, despite lower calcium levels in all the 72 h 
explants compared with 21 d results. The mean calcium 
and phosphorus levels in the pretreated GPBP 72 h 
explants did not statistically differ significantly for all 
the drug pre-incubation groups and control groups 
(Table 2). Except for the APD group, all pre-incubations 
which resulted in inhibition of calcification after 21 d, 
compared to the control, also demonstrated lower AP 
levels than control in the 72 h explant specimens 
(Figure 2). Morphological assessment qualitatively con- 
firmed these results (Figures 2 and 3). Although covalently 
bound APD significantly inhibited calcification in 21 d 
explants compared to controls (which were heavily 
calcified), maximal AP levels for all groups at 21 d were 
noted in the APD group (Figures 2 and 3). In contrast, 
pretreatment with NaEHDP did not inhibit GPBP 
calcification compared to control after 21 d, although the 
AP activity was sightly lower than the control in 72 h and 
21 d explants. 
Ga(NO,), (0.1 M) and FeCl, (10e4 M) pre-incubations 
failed to inhibit calcification. However, FeCl, (0.1 M) and 
AlCl, (0.1 M] pre-incubations inhibited calcification, and 
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Figure 1 a, Alkaline phosphatase (AP) activity levels normalized 
per extractable protein content and b, calcium levels/mg dry 
weight of GPBP control tissues and drug-treated tissues at 
initiation stage of calcification (72 h) and at 21 d interval 
calcification. 1111 q IIII, control (Ctrl) (pH 7.4); -0-, 
aminohydroxypropanediphosphonate (APO) (0.1 M); __C_, 
NaEHDP(O.l M);IIII~IIII,C~~I(~H~);-~, FeCI,(O.l M); 
-[7---, FeCI, (low4 M); -A-, Ga(NO,), (0.1 M); 
-A-, AICI, (0.1 M). 
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Figure 2 Effects of pretreatment in AK& and aminodiphosphonate (APD) on histochemical staining of alkaline phosphatase (AP) 
accumulation in bovine pericardium implanted subcutaneously in rats. a, and b, Control (untreated) bovine pericardium at 3 and 
21 d, respectively. c, AICI, pre-incubated bovine pericardium following 3 d implantation. d and e, APD pretreated tissue at 3 and 21 d, 
respectively. AP (dark reaction product) is evident in the control bioprosthetic tissue, a, b, at 3 d and is comparatively reduced at 
21 d. AP activity is scarcely evident in 72 h AICI, explants, c. However, AP activity is enhanced compared to controls at both 3 and 
21 d, d, e, in the APD-pretreated tissue. Original magnification x230. 
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a 
Figure 3 Light microscopy appearance of calcification of bovine pericardium implanted subcutaneously in 3 wk old rats for 21 d. 
a, Control tissue demonstrating heavy mineralization. b, Tissue pretreated in APO demonstrating sparse punctate calcific deposits 
(probably in cells). c, Tissue pretreated in FeCI, (0.1 M), demonstrating complete absence of mineralization. d, Tissue pretreated in 
gallium, demonstrating heavy mineralization. Each stained with von Kossa stain (calcium phosphate black). Original magnification x 120. 
decline in AP (21 d versw 72 h) of the various groups. AP 
activities in the Ga3+ group were slightly lower than 
controls after 72 h, and even slightly greater than 
controls after 21 d. Nevertheless, Gas+ failed to inhibit 
calcification. Ga3+ explants demonstrated the highest P 
levels of all groups after 21 d. These may nucleate further 
Ca-P deposition. 
Ca/P molar ratios of the 21 d explant groups demon- 
strated were consistent with the presence of calcium 
phosphate for the control groups and the FeCl, (low4 M) 
specimens. However, the calcified GafNO,), and NaEHDP 
groups each demonstrated a relatively higher phosphorus 
content and hence lower CaiP ratios than usually noted 
with hydroxyapatite deposition. 
DISCUSSION 
Interestingly, peak GPBP AP activities were noted on the 
72 h explants regardless of pre-incubation in solutions 
of diphosphonates or metallic ions. Earlier results showed 
that AP activity peaks in the first 72 h in control GPBP rat 
subdermal explants: by this time calcification is also 
initiated”. However, comparisons between the various 
groups (control and pre-incubation) did not reveal a trend 
consistently linking reduced GPBP with inhibition of 
calcification. Thus, although AP activity and inhibition 
of AP may be associated with the onset and progression 
of GPBP calcification, the present results support the 
view that AP may be one of several determinants of the 
pathogenesis of GPBP calcification. Therefore, AP inhibi- 
tion or enhancement by various inhibitors may not reveal 
the importance of AP in this setting. 
Furthermore, previous work from our group has 
shown that extrinsic GPBP AP activity declines following 
its peak at 72 h as mineralization progresses. Comparable 
observations were reported in studies of the onset of bone 
mineralization involving endochondral MV calcification”. 
In the case of MVs, this decline in AP activity is not due 
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to proteolysis, but rather to the calcification process 
itself”. The direct inhibitory effect of hydroxyapatite on 
AP, along with the loss of metal ions from the AP active 
site, are thought to contribute to the decline in AP 
activity during MV calcification. This mechanism may 
also be operative in GPBP calcification. 
The mechanism by which AP activity is promoted in 
GPBP mineralization is not yet understood. AP-active 
sites are activated by metal ions’s, such as Zn2+ and 
Mg’+. The A13+, Fe3+ and Ga3+ ions probably can compete 
with Zn2+ and Mgz+ at the enzyme’s metallo-binding 
sites, and thereby inhibit the phosphohydrolase activity. 
The A13+, Fe3+ and Ga3+ ions (10-l M) in the GPBP tissues 
were able to inhibit AP activity, although less so with 
Ga3+ than the others. However, despite this level of 
enzyme inhibition by the Ga(NO,), pre-incubation, this 
pretreatment was not effective in inhibiting calcification. 
These results further suggest that, although AP activity 
may be associated with the onset and progression of 
GPBP mineralization, it may not be causal or essential for 
the pathogenesis. 
Furthermore, earlier work has shown that either A13+ 
or Fe3+ salts act by binding to devitalized GPBP cells, and 
to membrane loci that are rich in phosphorus, thereby 
preventing the crystallization of hydroxyapatite at these 
sites”. It may be argued that Fe3+ or A13+ lowered AP 
levels in our studies by a critical increment, thereby 
reducing GPBP calcification. However, A13+, Fe3+ and 
other metal ions can inhibit mineralization by other 
mechanisms. A13+ ions can absorb on to hydroxyapatite 
crystals and severely inhibit both hydroxyapatite formation 
and dissolution in vitrozgl 30. Many metals can interfere 
with hydroxyapatite crystal growth in vitro by either 
competing with Ca ‘+ for sites in the crystal lattice or by 
adsorbing to the crystal surface3’. A13+ and Zn2+ are 
found to inhibit MV mineralization3’. Similarly, in the 
GPBP subdermal rat implants, the lowest molecular 
weight metal ions (Al < Fe < Ga, according to atomic 
weight] showed the strongest inhibitory effects on GPBP 
calcium accumulation. In fact, the greater the molecular 
weight of the metal atom of interest, the lower degree of 
calcification inhibition noted. A13+, the smallest ion in 
relation to Fe3+ and Ga3+ was the most effective in 
calcification inhibition: Ga3+cation which is the largest 
metal ion (used in this study] was unable to prevent GPBP 
calcification. Furthermore, the higher phosphorus content 
of the Ga3+ 21 d explants suggests that high levels of non- 
apatitic phospho-mineral (perhaps Ga-phosphates) may 
be predisposed to form after Ga3+ pretreatment. Therefore, 
these metallic ion pretreatments may be associated with 
unusual phospho-mineral complexes involving, perhaps, 
phospholipids or metallo-phosphates other than hydroxy- 
apatite. However, the present experimental design does 
not permit a conclusive resolution of these issues. 
APD pre-incubation inhibited GPBP calcification, but 
was associated with AP activity higher than controls. 
APD in clinical use has been associated with adverse 
effects related to cytotoxicity, as well as inflammatory 
gastrointestinal and dermatologic side effects33’34. The 
morphological results in the present study demonstrated 
an exuberant inflammatory response to the APD implants, 
and thus the higher level of AP may reflect enzyme 
activity from inflammatory cells or cells damaged due to 
toxic processes, rather than calcification-related events. 
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It would have been helpful in this regard to have 
quantitated the extent of inflammatory cell infiltration, 
However, this was beyond the scope of the present 
studies. Furthermore, earlier results from our group have 
shown that APD pre-incubation of GPBP was associated 
with unstable covalent binding of APD to GPBP. Thus 
APD is continuously leaching out of the tissue, and may 
thereby cause regional toxicity near the GPBP implant, 
which could lead to increased AP activity related to 
inflammation, but probably spatially dissociated and 
unrelated to calcification. 
Conversely, NaEHDP pre-incubation, which did not 
inhibit calcification, resulted in a slightly lower AP 
activity in the 72 h explants compared to the controls. 
However, the net decline in AP activity for the NaEHDP 
explant groups was comparable to that of calcified 
controls (Figure I). Furthermore, previous work from 
our group has demonstrated that NaEHDP rapidly 
diffuses out of GPBP tissue following pre-incubation, 
unlike Fe3+, A13+ and APD, which remain more closely 
associated with GPBP tissue35. Thus, no persistent 
anticalcification effects occurred in the NaEHDP group, 
and the decline in AP activity was comparable to 
controls, as might be expected. In addition, elevated 
phosphorus levels were noted in the calcified 21 d 
NaEHDP explants, in which a Ca/P molar ratio was 
noted comparable to that of the Ga explants. 
CONCLUSIONS 
The peak levels of AP in rat subdermal GPBP implants 
were noted at 72 h in both controls and specimens 
pretreated with either calcification inhibitors, or related 
compounds which did not inhibit calcification. Thus, 
peak GPBP AP activity was present at 72 h, regardless of 
pretreatment conditions. 
All inhibitors of calcification [except APD) were 
associated with lower 72 h AP levels than controls, 
including pretreatments ineffective for calcification 
inhibition, such as Ga”+ and EHDP. Thus reduced AP at 
72 h is not related to inhibition of calcification. 
Therefore, the results of the present experiments support 
the view that peak AP (72 h) is not necessarily associated 
with the ultimate progression GPBP calcification. 
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